Rxo (RXO) Common Equity (2021 - 2026)

Rxo (RXO) has reported Common Equity for 6 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.

• Common Equity for Q1 2026 came in at $1.5 billion, down 4.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 4.91% YoY), and the FY2025 annual result was $1.5 billion, down 4.4% from the prior year.
• Common Equity was $1.5 billion for Q1 2026 at Rxo, down from $1.5 billion in the prior quarter.
• Over five years, Common Equity peaked at $1.7 billion in Q3 2024 and troughed at $579.0 million in Q2 2024.
• Average Common Equity over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2022.
• Year-over-year, Common Equity tumbled 50.88% in 2023 and jumped 180.0% in 2024.
• Over 5 years, Common Equity stood at $587.0 million in 2022, then rose by 1.19% to $594.0 million in 2023, then surged by 171.38% to $1.6 billion in 2024, then fell by 4.4% to $1.5 billion in 2025, then slipped by 2.08% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.6 billion in Q3 2025.